Biogen Idec and Isis Pharmaceuticals target spinal muscular atrophy

Friday, January 6, 2012 09:58 AM

Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, global option and partnership agreement under which they will jointly develop and commercialize ISIS-SMNRx, an antisense investigational drug that treats spinal muscular atrophy (SMA) by compensating for the underlying genetic defect that causes the disease.

The agreement awards Isis an upfront payment of $29 million, with the possibility to receive up to $45 million in milestone payments. While Isis will be responsible for global development of ISIS-SMNRx through phase II/III trials, Biogen Idec has the option to license ISIS-SMNRx until a successful phase II/III trial is completed. If Biogen Idec exercises its option, it will assume global development, regulatory, and commercialization responsibilities.

"SMA is a heartbreaking disease -- it can kill children before their second birthday and there are currently no therapies to treat the disease," said George A. Scangos, Ph.D., CEO of Biogen Idec. “Isis's antisense compound has the potential to be a highly effective, first-to-market therapy for this deadly disease.”

Isis initiated the first phase I clinic study evaluating ISIS-SMNRx in children with SMA in December 2011. Isis plans to follow this study with a phase I multiple-dose study.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs